| No. | Cell Type | Patent No. | Disease | Summary | Trial Status | Route of Administration | Refs. |
|---|---|---|---|---|---|---|---|
| 1 | Neuroretina-derived Retinal Stem Cells (NRSC) | US2003/0207450A1 | Retinal dystrophy | The patent explains a system for the first successful isolation of stem cells from neural retinal tissues which have capability of self-renewal, multipotency and retina-specific differentiation. In one of the embodiments, the neuroretinal tissue from aged donors was also used for stem cell production. | Pre-clinical | - | [52] |
| 2 | Mammalian Multipotent Neural Stem Cells (MNSCs) | US2003/0148513A1 | Disorders affecting vision like, neurodegenerative disease, autoimmune disorder, corporal disease, neurotoxic disease, a demyelinating disorder etc. | The invention defines reagents and methods used to produce neural stem cells, to treat neurological and corporal disorders. The art also provides pharmaceutical compositions which can be administered to animal models to check for effect and efficiency. For production of retinal stem cells the stem cells are cultured in a media containing growth factors like TGF-b3, CNTF and IGF-1 individually or in combination which is used to treat retinal defects. | Pre-clinical | Injection to the target site or transplantation | [53] |
| 3 | Neuroretinal Cells | US2011/0004304A1 | - | The patent illustrates a bioreactor comprising of three layers made of microchannels, polymer scaffold and thin film membrane embedded with RPE cells used for culturing retinal cells or tissues. The bioreactor layers mimic the retinal structure and offer spatial organization. | - | - | [54] |